Shots: Abbott has launched the IonicRF Generator, which is used to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system Radiofrequency ablation uses an electric current to heat up a small area of nerve tissue to stop it from sending pain signals. Studies showed that pain relief following a […]Read More
Shots: King’s and Wellcome to receive $340M as development and commercial milestone and royalties on sales. MSD to get a license for conducting lead optimization, preclinical & clinical research The focus of an agreement is to develop therapies for chronic pain and to meet unmet medical needs of patients Professor McNaughton at King’s identifies target […]Read More
Shots: TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders The focus of the agreement is to develop non-opioid therapies with advancement […]Read More
Shots: The P-III OA study involves assessing of tanezumab (2.5mg/5mg, SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA pain of the knee or hip across EU and Japan for 24 wks. The study showed a meeting in all 1EPs improvement in pain, physical function with well-tolerated results and has shown […]Read More
Shots: Lilly to acquire Hydra, in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling, further initiate clinical trials Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective cation channels indicated for the treatment […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
